Ptpn22 promotes immunization responses to Influenza A (P4043)

Abstract

Abstract A variant allele of PTPN22 is a potent susceptibility factor for autoimmune diseases, including Rheumatoid Arthritis and Type I Diabetes. Ptpn22 is required in myeloid cells for selective promotion of Toll-Like Receptor signaling leading to Type I IFN production. Since Type I IFN are essential for anti-viral immunity and for efficient responses to viral immunization, we investigated the role of PTPN22 in response to vaccination. We tested the ability of Ptpn22 knockout mice to mount a protective immune response to vaccination against Influenza A virus. We found that Ptpn22 is required for efficient generation of both influenza-specific cytotoxic T lymphocyte and neutralizing humoral responses after vaccination with inactivated influenza. Further, upon challenge with live influenza, vaccinated Ptpn22 KO animals exhibit increased mortality, suggesting that defects in antibody and CTL responses associated with Ptpn22 deficiency result in decreased protection engendered by inactivated influenza vaccination. These findings indicate a requirement for Ptpn22 in protective immune responses to influenza vaccine. Moreover, they suggest that further studies of vaccine responsiveness should be mounted in human carriers of the disease-associated PTPN22 variant, since such carriers exhibit diminished Toll-Like Receptor-induced Type I IFN production by myeloid cells.